- Home
- FDMT
as 12-20-2024 4:00pm EST
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 420.7M | IPO Year: | 2020 |
| Target Price: | $42.80 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.58 - $36.25 | Next Earning Date: | 11-13-2024 |
| Revenue: | $17,000 | Revenue Growth: | -99.92% |
| Revenue Growth (this year): | -78.91% | Revenue Growth (next year): | 87.55% |
Latest 4D Molecular Therapeutics Inc. News
FDMT Breaking Stock News: Dive into FDMT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
Insider Monkey
a month ago
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now
GlobeNewswire
a month ago
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
MT Newswires
a month ago
RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk
Zacks
a month ago
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Simply Wall St.
2 months ago
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
Zacks
2 months ago
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
Compare FDMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FDMT 4D Molecular Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.